Biochemoprevention for dysplastic lesions of the upper aerodigestive tract

Archives of Otolaryngology - Head and Neck Surgery

Volumn 125, Issue 10, 1999, Pages 1083-1089

  Papadimitrakopoiilou, Vflli A ^a   Dayman, Gary L ^a   Shin, Dong M ^a   Myers, Jeffrey N ^a   Gulcnwatcr, Ann M ^a   Goepfcrt, Helmuth ^a   El Naggar, Adel K ^a   Lewin, Jan S ^a   Lippman, Scott M ^a   Hong, Wann K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; BETA CAROTENE; ISOTRETINOIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER RISK; CHEILITIS; CHEMOPROPHYLAXIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MIXTURE; FATIGUE; FEMALE; FEVER; HUMAN; HYPERTRIGLYCERIDEMIA; LARYNX DISORDER; LARYNX DYSPLASIA; MALE; MALIGNANT TRANSFORMATION; ORAL DRUG ADMINISTRATION; PRECANCER; SKIN TOXICITY;

EID: 0032824170     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.125.10.1083     Document Type: Article

References (33)

1. Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. Cancer. 1984;53:563-568.
2. Blackwell KE, Calacaterra TC, Fu Y-S. Laryngeal dysplasia: epidemiology and treatment outcome. Ann Otol Rhinol Laryngol. 1995;104:596-602.
3. Plch J, Par I, Navratilova I, Blahova M, Zavadil M. Long term follow-up study of laryngeal precancer. Auris Nasus Larynx. 1998:25:407-412.
4. De Vesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni JF. Recent cancer trends in the United States. J Natl Cancer Inst. 1995:87:175-182.
5. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. JClin Oncol. 1994; 12:851-873.
6. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer. 1988:41:184-197.
7. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1998. CA Cancer J Clin. 1998:48:6-30.
8. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. NEnglJMed. 1993:328:184-194.
9. Slaughter DP, Southv/ick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer. 1953; 6:963-968.
10. Farber E. The multistep nature of cancer development. Cancer Res. 1984;44: 4217-4223.
11. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. NEnglJMed. 1990:323:795-801.
12. Hong WK, Endicott J, Itri LM, et al. 13-c/s-retinoic acid in the treatment of oral leukoplakia. NEnglJMed. 1986:315:1501-1505.
13. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose 13cRA with beta carotene to prevent oral carcinogenesis. NEng/JMed. 1993;328:15-20.
14. Kim HJ, Lee JS, Shin DM, et al. Chromosomal instability, p53 expression and retinoid response in oral premalignancy [abstract]. ProcAm Soc Clin Oncol. 1995; 14:81.
15. Banner SE, Winn RJ, Lippman SM, et al. Regression of oral leukoplakia with a-tocopherol: a community clinical oncology program chemoprevention study. JNatl Cancer Inst. 1993:85:44-47.
16. Calhoun KH, Stanley D, Stiernberg CM, Ahmed AE. Vitamins A ant) E do protect against oral carcinoma. Arch Otolaryngol Head Neck Surg. 1989;115: 484-488.
17. Besa EC, Abraham JL, Bartholomew MJ, et al. Treatment with 13-c/s-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of a-tocopherol. AmJMed. 1990:89:739-747.
18. Kolla V, Lindner DJ, Wehua X, Borden EC, Kalvakolanu DV. Modulation of Interferon (IFN)-inducible gene expression by retinoic acid. J Biol Chem. 1996;271 : 10508-10514.
19. Moore DM, Kalvakolanu DV, Lippman SM, et al. Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematol. 1994;31(suppl 5):31-37.
20. Zubrod CG, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and trimethylene thiophosphoramide. J Chronic Dis. 1960;11:7-33.
21. Ajani JA, Welch SR, Raber MM, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990:8:147-159.
22. Freije JE, Beatty TW, Campbell BH, Woodson BT, Schultz CJ, Toohill RJ. Carcinoma of the larynx in patients with gastroesophageal reflux. Am J Otolaryngol. 1996:17:386-390.
23. Prades J-M, Martin C, Boucheron S. Dysplasies laryngées sévères et retinoide de synthèse [Severe laryngeal dysplasia and synthetic retinoids]. Ann Otolaryngol Chir Cervicofac (Paris). 1937;104:21-27.
24. Issing WJ, Struck R, Naumann A. Long-term follow-up of larynx leukoplakia under treatment with retinyl palmitate. Weacwec.1996;18:560-565.
25. Mao L, EI-Naggar AK, Papadimitrakopoulou V, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J tJatl Cancer Inst. 1998:90:1545-1551.
26. Shin DM, Mao LM, Papadimitrakopoulou VA, et al. Alteration of p53 gene and protein expression and biochemopreventive therapy in patients with advanced premalignant lesions of the head and neck. J Natl Cancer Inst. In press.
27. Lotan R. Retinoids and apoptosis: implications for cancer chemoprevention and therapy [editorial comment]. J Natl Cancer Inst. 1995:87:1655-1657.
28. Oridate N, Lotan D, Xu XC, Hong WK, Lotan R. Differential induction of apoptosis by all-rrans retinoic acid and Af-(4-hydroxyphenyl)retinamide in human squamous ceil carcinoma ceil lines. Clin Cancer Res. 1996:2:855-863.
29. Delia D, Aiello A, Lombard! L, et al. N-(4-nydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res. 1993:53:6036-6041.
30. Chiesa F, Tradati N, Marazza M, et al. W-(4-hydroxyphenyl) retinamide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem. 1993;17(suppl F): 255-261.
31. Rotsmenz N, de Palo G, Formelli F, et al. Long-term tolerability of fenretinide (4HPR) in breast cancer patients. Eur J Cancer. 1991:27:1127-1131.
32. Decensi A, Costa A, De Palo G, et al. Retinoid-menopause interactions in a breast cancer prevention trial [abstract]. ProcAmAssoc Cancer Res. 1997:38:529.
33. De Palo G, Veronesi U, Camerini T, et al. Can fenretinide protect women against ovarian cancer? J Natl Cancer Inst. 1995:87:146-147.